First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration

AIDS

Volumn 24, Issue 7, 2010, Pages 1043-1050

  Drylewicz, Julia ^a,b   Eholie, Serge ^c   Maiga, Moussa ^d   Zannou, Djimon Marcel ^e   Sow, Papa Salif ^f   Ekouevi, Didier K ^a,g   Peterson, Kevin ^g   Bissagnene, Emmanuel ^c   Dabis, François ^a,b   Thiébaut, Rodolphe ^a,b  

^a INSERM   (France)

^b Centre Hospitalier Universitaire (CHU) de Treichville   (France)

^c Service d'Hépato Gastro Entérologie   (Somalia)

^d Du Centre Hospitalier Universitaire (CHNU)   (France)

^e Centre Hospitalier Universitaire Dakar   (Senegal)

^f CHU de Treichville   (France)

^g MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

Author keywords

Africa; Antiretroviral therapy; CD4+ T lymphocytes; HIV 1; HIV 2; Longitudinal study

Indexed keywords

RNA DIRECTED DNA POLYMERASE INHIBITOR;

AFRICA; ARTICLE; BENIN; CD4+ T LYMPHOCYTE; CELL COUNT; CONTROLLED STUDY; GAMBIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALI; PRIORITY JOURNAL; SENEGAL;

ADULT; AFRICA, WESTERN; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HIV-2; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL; VIRAL LOAD; YOUNG ADULT;

EID: 77950919420     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283377a06     Document Type: Article

References (44)

1. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2008. Geneva: WHO; 2008.
2. van der Loeff MF, Awasana AA, Sarge-Njie R, van der Sande M, Jaye A, Sabally S, et al. Sixteen years of HIV surveillance in a West African research clinic reveals divergent epidemic trends of HIV-1 and HIV-2. Int J Epidemiol 2006; 35:1322-1328.
3. Eholie S, Anglaret X. Commentary: decline of HIV-2 prevalence in West Africa: good news or bad news? Int J Epidemiol 2006; 35:1329-1330.
4. Valadas E, Franca L, Sousa S, Antunes F. 20 Years of HIV-2 infection in Portugal: trends and changes in epidemiology. Clin Infect Dis 2009; 48:1166-1167.
5. Whittle H, Morris J, Todd J, Corrah T, Sabally S, Bangali J, et al. HIV-2-infected patients survive longer than HIV-1-infected patients. AIDS 1994; 8:1617-1620.
6. Berry N, Ariyoshi K, Jaffar S, Sabally S, Corrah T, Tedder R, Whittle H. Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. J Hum Virol 1998; 1:457-468.
7. MacNeil A, Sarr AD, Sankale JL, Meloni ST, Mboup S, Kanki P. Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J Virol 2007; 81:5325-5330.
8. Martinez Steele E, Awasana AA, Corrah T, Sabally S, van der Sande M, Jaye A, et al. Is HIV-2-induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic. AIDS 2007; 21:317-324.
9. van der Loeff MFS, Martinez Steele E, Corrah T, Awasana AA, van der Sande M, Sarge Njie R, et al. HIV-2-induced AIDS different from HIV-1-associated AIDS? AIDS 2008; 22:791-792.
10. Schutten M, van der Ende ME, Osterhaus AD. Antiretroviral therapy in patients with dual infection with human immunodeficiency virus types 1 and 2. N Engl J Med 2000; 342:1758-1760.
11. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antiviral Ther 2004; 9:57-65.
12. Matheron S, Damond F, Benard A, Taieb A, Campa P, Peytavin G, et al. CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5HIV-2 cohort. AIDS 2006; 20:459-462.
13. Jallow S, Kaye S, Alabi A, Aveika A, Sarge Njie R, Sabally S, et al. Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia. AIDS 2006; 20:1455-1458.
14. Drylewicz J, Matheron S, Lazaro E, Damond F, Bonnet F, Simon F, et al. Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. AIDS 2008; 22:457-468.
15. Smith RA, Anderson DJ, Pyrak CL, Preston BD, Gottlieb GS. Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance. J Infect Dis 2009; 199:1323-1326.
16. Borget MY, Diallo K, Adje-Toure C, Chorba T, Nkengasong JN. Virologic and immunologic responses to antiretroviral therapy among HIV-1 and HIV-2 dually infected patients: case reports from Abidjan, Cote d'Ivoire. J Clin Virol 2009; 45:72-75.
17. Benard A, Damond F, Campa P, Peytavin G, Descamps D, Lascoux-Combes C, et al. Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients. AIDS 2009; 23:1171-1173.
18. Sarfo FS, Bibby DF, Schwab U, Appiah LT, Clark DA, Collini P, et al. Inadvertent nonnucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in dual HIV-1/2 and HIV-2 seropositive West Africans: a retrospective study. J Antimicrob Chemother 2009; 64:667-669.
19. Jallow S, Alabi A, Sarge-Njie R, Peterson K, Whittle H, Corrah T, et al. Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants. J Clin Microbiol 2009; 47:2200-2208.
20. Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to nonnucleoside inhibitors. Proc Natl Acad Sci USA 2002; 99:14410-14415.
21. Brower ET, Bacha UM, Kawasaki Y, Freire E. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Design 2008; 71:298-305.
22. Descamps D, Damond F, Matheron S, Collin G, Campa P, Delarue S, et al. High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleo-side reverse transcriptase inhibitors containing regimen. J Med Virol 2004; 74:197-201.
23. Gottlieb GS, Badiane NMD, Hawes SE, Fortes L, Toure M, Ndour CT, et al. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resource-limited West Africa. Clin Infect Dis 2009; 48:476-483.
24. Landman R, Damond F, Gerbe J, Brun Vezinet F, Yeni P, Matheron S. Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients. AIDS 2009; 23:426-428.
25. Jallow S, Vincent T, Leligdowicz A, De Silva T, Van Tienen C, Alabi A, et al. Presence of a multidrug-resistance mutation in an HIV-2 variant infecting a treatment-naive individual in Caio, Guinea Bissau. Clin Infect Dis 2009; 48:1790-1793.
26. Toure S, Kouadio B, Seyler C, Traore M, Dakoury Dogbo N, Duvignac J, et al. Rapid scaling-up of antiretroviral therapy in 10000 adults in Cote d'Ivoire: 2-year outcomes and determinants. AIDS 2008; 22:873-882.
27. International epidemiologic databases to evaluate AIDS: West Africa. URL: http://www.iedeawestafrica.org; Last access 25 January 2010.
28. Brinkhof MW, Boulle A, Weigel R, Messou E, Mathers C, Orrell C, et al. Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality. Plos Med 2009; 6:e1000066.
29. Hounton SH, Akonde A, Zannou DM, Bashi J, Meda N, Newlands D. Costing universal access of highly active antire-troviral therapy in Benin. AIDS Care 2008; 20:582-587.
30. Boileau C, Nguyen VK, Sylla M, Machouf N, Chamberland A, Traore HA, et al. Low prevalence of detectable HIV plasma viremia in patients treated with antiretroviral therapy in Burkina Faso and Mali. J Acquir Immune Defic Syndr 2008; 48:476-484.
31. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, Laniece I, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 2006; 20:1181-1189.
32. Sow PS, Otieno LF, Bissagnene E, Kityo C, Bennink R, Cleven-bergh P, et al. Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries. J Acquir Immune Defic Syndr 2007; 44:262-267.
33. Thiébaut R, Walker S. When it is better to estimate a slope with only one point. QJM Quater J Med 2008; 101:821-824.
34. Rouet F, Ekouevi DK, Inwoley A, Chaix ML, Burgard M, Bequet L, et al. Field evaluation of a rapid human immunodeficiency virus (HIV) serial serologic testing algorithm for diagnosis and differentiation of HIV type 1 (HIV-1), HIV-2, and dual HIV-1-HIV-2 infections in West African pregnant women. J Clin Microbiol 2004; 42:4147-4153.
35. Pakker NG, Notermans DW, de Boer RJ, Roos MT, de Wolf F, Hill A, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nature Med 1998; 4:208-214.
36. Jacqmin Gadda H, Sibillot S, Proust C, Molina JM, Thiébaut R. Robustness of the linear mixed model to misspecified error distribution. Computat Stat Data Anal 2007; 51:5142-5154.
37. Thiébaut R, Jacqmin-Gadda H, Babiker A, Commenges D. Joint modelling of bivariate longitudinal data with informative dropout and left-censoring, with application to the evolution of CD4Rcell count and HIV RNA viral load in response to treatment of HIV infection. Stat Med 2005; 24:65-82.
38. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296:782-793.
39. Nash D, Katyal M, Brinkhof MW, Keiser O, May M, Hughes R, et al. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS 2008; 22:2291-2302.
40. Pujades-Rodriguez M, O'Brien D, Humblet P, Calmy A. Second-line antiretroviral therapy in resource-limited settings: the experience of Medecins Sans Frontieres. AIDS 2008; 22:1305-1312.
41. Souville M, Msellati P, Carrieri MP, Brou H, Tape G, Dakoury G, Vidal L. Physicians' knowledge and attitudes toward HIV care in the context of the UNAIDS/Ministry of Health Drug Access Initiative in Cote d'Ivoire. AIDS 2003; 17 (Suppl 3):S79-S86.
42. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach:-2006 revision. Geneva: WHO; 2006.
43. Gottlieb GS, Eholie SP, Nkengasong JN, Jallow S, Rowland-Jones S, Whittle HC, Sow PS. A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa. AIDS 2008; 22:2069-2072.
44. Matheron S. HIV-2 infection: a call for controlled trials. AIDS 2008; 22:2073-2074.